Milestones and perspectives in coagulation and hemostasis

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 1, 2009, Pages 9-22

  Lippi, Giuseppe ^a,d   Favaloro, Emmanuel J ^b   Franchini, Massimo ^c   Guidi, Gian Cesare ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Coagulation; Hemorrhage; Hemostasis; History; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; HEPARIN; PROTEIN C; PROTEIN S; VON WILLEBRAND FACTOR;

BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CLINICAL FEATURE; DISEASE COURSE; HEMOSTASIS; HUMAN; MEDICINE; MUTATION; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY; THROMBOPHILIA;

ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; FACTOR V; FACTOR VII; HEMOSTASIS; HEPARIN; HUMANS; MUTATION; PLATELET AGGREGATION; POLYMORPHISM, GENETIC; THROMBELASTOGRAPHY; VON WILLEBRAND FACTOR;

EID: 63149161130     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1214144     Document Type: Review

References (112)

1. al-Qasim Khalaf A, al-Andalusi al-Zahraw A. Medical treatise Kitab al-tasrîf liman ajaza an al-talîf fi al-tibb. Available at: http://www.museumwnf.net/database-item.php?id=object;ISL;ma;Mus01-F;16;en. Accessed February 27, 2009
2. Schultze M. Ein heizbarer Objecttisch und seine Verwendung bei Untersuchungen des Blutes. Arch Mikrosc Anat 1865;1:1-42
3. Bizzozero J. Über einen neuen Forrnbestandteil des Blutes und dessen Rolle bei der Thrombose und Blutgerinnung. Arch Pathol Anat Physiol Klin Med 1882;90:261-332
4. Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. Br J Haematol 2006;133:251-258
5. Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007;33:273-282
6. Briggs C, Harrison P, Machin SJ. Continuing developments with the automated platelet count. Int J Lab Hematol 2007;29:77-91
7. Singh H, Chaudhary R, Ray V. Platelet indices as quality markers of platelet concentrates during storage. Clin Lab Haematol 2003;25:307-310
8. Abe Y, Wada H, Sakakura M, et al. Usefulness of fully automated measurement of reticulated platelets using whole blood. Clin Appl Thromb Hemost 2005;11:263-270
9. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; in press
10. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. Guidelines on platelet function testing. J Clin Pathol 1988;41:1322-1330
11. Ivy AC, Nelson D, Buchet C. The standardization of certain factors in the cutaneous "venostasis" bleeding time technique. J Lab Clin Med 1941;26:1812-1941
12. Favaloro EJ, Smith J, Petinos P, Collecutt M, Street A, Hertzberg Mon behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel. Laboratory testing, diagnosis and management of von Willebrand's disease: current practice in Australasia. Am J Clin Pathol 1999;112:712-719
13. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyser using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331
14. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-2552
15. De Caterina R, Lanza M, Manca G, Strata GB, Maffei S, Salvatore L. Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 1994;84:3363-3370
16. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929
17. McGlasson D, Fritsma GA. Whole blood aggregometry. Semin Thromb Hemost 2009; in press
18. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009; in press
19. Cardigan R, Turner C, Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005;88:153-163
20. Favaloro EJ. Internal quality control and external quality assesment of platelet function tests. Semin Thromb Hemost 2009; in press
21. Hartert H. Blutgerinnungsstudien mit der Thrombeastographie, einem neuen Untersuchungsverfahren. Klin Wochenschr 1948;26:577-583
22. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005;27:81-90
23. Adams M, Ward C, Thom J, et al. Emerging technologies in hemostasis diagnostics: a report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group. Semin Thromb Hemost 2007;33:226-234
24. Watson HG, Greaves M. Can we predict bleeding? Semin Thromb Hemost 2008;34:97-103
25. Dempfle CE, Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008;34:445-450
26. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 1973;5:167-179
27. Kratzer MA, Born GV. Simulation of primary haemostasis in vitro. Haemostasis 1985;15:357-362
28. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34:709-733
29. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 1999;99:620-625
30. Varon D, Savion N. Cone and platelet analyzer. In Michelson AD, ed. Platelets. London, UK: Academic Press; 2002:337-345
31. Harrison P, Mumford A. Screening tests of platelet function - update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009; in press
32. Rinder HM. Platelet function testing by flow cytometry. Clin Lab Sci 1998;11:365-372
33. Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost 2007;33:771-779
34. Liu J, DeNofrio J, YuanW,Wang Z,McFaddenAW, Parise LV. Genetic manipulation of megakaryocytes to study platelet function. Curr Top Dev Biol 2008;80:311-335
35. Senzel L, Gnatenko DV, Bahou WF. Genomic and proteomic applications in diagnosis of platelet disorders and classification. Semin Thromb Hemost 2008;34:532-538
36. Franchini M, Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 2007;44:115-149
37. von Willebrand EA. Hereditar pseudohemofili. Finska Lak-Sallsk Handl 1926;67:87-112
38. Nilsson IM, Blomback M, Jorpes E. Von Villebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957;159:179-188
39. Zimmerman TS, Ruggeri ZM. Coagulation and Bleeding Disorders: The Role of Factor VIII and von Willebrand Factor. New York, NY: Marcel Dekker; 1989
40. Owen WG, Wagner RH. Antihemophilic factor: separation of an active fragment following dissociation by salts or detergents. Thromb Diath Haemorrh 1972;27:502-515
41. Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985;228:1401-1406
42. Lynch DC, Zimmerman TS, Collins CJ, et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985;41:49-56
43. Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A 1985;82:6394-6398
44. Federici AB, Castaman G, Mannucci PM; Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002;8:607-621
45. Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006;32:456-471
46. Favaloro EJ. An update on the von Willebrand factor collagen binding (VWF:CB) assay: 21 years of age and beyond adolescence, but not yet a mature adult. Semin Thromb Hemost 2007;33:727-744
47. Howard MA, Firkin BG. Ristocetin - a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971;26:362-369
48. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973;52:2708-2716
49. Favaloro EJ, Bonar R, Marsden K (on behalf of the RCPA QAP Haemostasis Committee). Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008;21:178-185
50. Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K (on behalf of the RCPA QAP in Haematology). 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD Thromb Haemost 2007;98:346-358
51. Kempfer AC, Silaf MR, Farias CE, et al. Binding of von Willebrand factor to collagen by flow cytometry. Am J Clin Pathol 1999;111:418-423
52. Chen D, Daigh CA, Hendricksen JI, et al. A highly sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost 2008;6:323-330
53. Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica 2007;92:1647-1654
54. Blombäck B. Fibrinogen: evolution of the structure-function concept. Keynote address at Fibrinogen 2000 Congress. Ann N Y Acad Sci 2001;936:1-10
55. Schmidt A. Neue Untersuchungen ueber die Fasserstoffesgerinnung. Pflueger's Arch F Ges Physiol 1872;6:413-538
56. Monroe DM, Hoffman M, Roberts HR. Fathers of modern coagulation. Thromb Haemost 2007;98:3-5
57. MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 1964;202:498-499
58. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312
59. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82:165-174
60. Hemker HC. The initiation phase - a review of old (clotting-) times. Thromb Haemost 2007;98:20-23
61. Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med 2007;45:2-12
62. McVey JH. Tissue factor pathway. Baillieres Best Pract Res Clin Haematol 1999;12:361-372
63. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007;27:1687-1693
64. Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII). Acta Haematol 1951;6:1-18
65. Eigenbrot C. Structure, function, and activation of coagulation factor VII. Curr Protein Pept Sci 2002;3:287-299
66. Franchini M, Veneri D, Lippi G. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplant 2007;39:729-735
67. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002;22:539-548
68. Römisch J. Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 2002;383:1119-1124
69. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003;1: 1138-1139
70. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 2007;33:563-572
71. Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age. Results from a large family cohort study. Circulation 2008;118:1659-1667
72. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348:1435-1441
73. Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost 2007;33:588-596
74. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007;370:1773-1779
75. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102
76. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-530
77. The European Genetics Foundation; The Cardiovascular Disease Educational and Research Trust; The International Union of Angiology; The Mediterranean League on Thromboembolism; Nicolaides AN, Breddin HK, Carpenter P, et al. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2005;24:1-26
78. van Boven HH, Vandenbroucke JP, Briët E, Rosendaal FR. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999;94:2590-2594
79. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost 2007;33:573-581
80. Marcum JA. The origin of the dispute over the discovery of heparin. J Hist Med Allied Sci 2000;55:37-66
81. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34:58-73
82. HowellWH, Holt E. Two new factors in blood coagulation - heparin and pro-antithrombin. Am J Physiol 1918;47: 328-341
83. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008;141:757-763
84. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004;30:703-713
85. Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother 2005;39:1275-1285
86. Bianchini P, Liverani L, Spelta F, Mascellani G, Parma B. Variability of heparins and heterogeneity of low molecular weight heparins. Semin Thromb Hemost 2007;33:496-502
87. Esmon CT. The protein C pathway. Chest 2003;124(3, Suppl):26S-32S
88. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-1373
89. Nizzi FA Jr, Kaplan HS. Protein C and S deficiency. Semin Thromb Hemost 1999;25:265-272
90. Martí-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2008;(1):CD004388
91. Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977;16:698-706
92. Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980;255:5521-5524
93. García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis of protein S deficiency. Thromb Haemost 2007;98:543-556
94. Comp PC, Esmon C. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984;311:1525-1528
95. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002;126:1349-1366
96. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
97. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008
98. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506
99. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522
100. Bauduer F, Lacombe D, Factor V. Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005;86:91-99
101. Rosendorff A, Dorfman DM. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med 2007;131:866-871
102. Norstrøm E, Thorelli E, Dahlbäck B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 2002;100:524-530
103. Steen M, Norstrom EA, Tholander AL, et al. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood 2004;103:3381-3387
104. Lunghi B, Iacoviello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996;75:45-48
105. Castaman G, Faioni EM, Tosetto A, Bernardi F. The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 2003;88:1182-1189
106. Tormene D, Fortuna S, Tognin G, et al. The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study. J Thromb Haemost 2005;3:1414-1420
107. Varga EA, Kerlin BA, Wurster MW. Social and ethical controversies in thrombophilia testing and update on genetic risk factors for venous thromboembolism. Semin Thromb Hemost 2008;34:549-561
108. Hertzberg M, Neville S, Favaloro EJ, MacDonald D. External quality assurance of DNA testing for thrombophilia mutations. Am J Clin Pathol 2005;123:189-193
109. Favaloro EJ. Diagnostic issues in thrombophilia: a laboratory scientist's view. Semin Thromb Hemost 2005;31:11-16
110. Favaloro EJ, Bonar R, Sioufi J, et al; on behalf of the RCPA QAP in Haematology. Multi-laboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program in Haematology. Semin Thromb Hemost 2005;31:49-58
111. Reitsma PH, Rosendaal FR. Past and future of genetic research in thrombosis. J Thromb Haemost 2007;5(Suppl 1):264-269
112. Bernardi E, Pesavento R, Prandoni P. Upper extremity deep venous thrombosis. Semin Thromb Hemost 2006;32:729-736